Philippe Garrigue1,2,3, Aurore Bodin-Hullin3, Laure Balasse1,2, Samantha Fernandez2, Wassim Essamet4, Françoise Dignat-George1, Karel Pacak5, Benjamin Guillet1,2,3, David Taïeb6,3. 1. Aix-Marseille University, INSERM, UMR-S 1076, Marseille, France. 2. Aix-Marseille University, CERIMED, Marseille, France. 3. Department of Nuclear Medicine, Aix-Marseille University, Marseille, France. 4. Department of Neuropathology, APHM Timone, Marseille, France; and. 5. Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland. 6. Aix-Marseille University, CERIMED, Marseille, France david.taieb@ap-hm.fr.
Abstract
In recent years, inherited and acquired mutations in the tricarboxylic acid (TCA) cycle enzymes have been reported in diverse cancers. Pheochromocytomas and paragangliomas often exhibit dysregulation of glucose metabolism, which is also driven by mutations in genes encoding the TCA cycle enzymes or by activation of hypoxia signaling. Pheochromocytomas and paragangliomas associated with succinate dehydrogenase (SDH) deficiency are characterized by high 18F-FDG avidity. This association is currently only partially explained. Therefore, we hypothesized that accumulation of succinate due to the TCA cycle defect could be the major connecting hub between SDH-mutated tumors and the 18F-FDG uptake profile. Methods: To test whether succinate modifies the 18F-FDG metabolic profile of tumors, we performed in vitro and in vivo (small-animal PET/CT imaging and autoradiography) experiments in the presence of succinate, fumarate, and phosphate-buffered saline (PBS) in different cell models. As a control, we also evaluated the impact of succinate on 18F-fluorocholine uptake and retention. Glucose transporter 1 (GLUT1) immunohistochemistry was performed to assess whether 18F-FDG uptake correlates with GLUT1 staining. Results: Intratumoral injection of succinate significantly increased 18F-FDG uptake at 24 h on small-animal PET/CT imaging and autoradiography. No effect of succinate was observed on cancer cells in vitro, but interestingly, we found that succinate caused increased 18F-FDG uptake by human umbilical vein endothelial cells in a concentration-dependent manner. No significant effect was observed after intratumoral injection of fumarate or PBS. Succinate, fumarate, and PBS have no effect on cell viability, regardless of cell lineage. Intramuscular injection of succinate also significantly increases 18F-FDG uptake by muscle when compared with either PBS or fumarate, highlighting the effect of succinate on connective tissues. No difference was observed between PBS and succinate on 18F-fluorocholine uptake in the tumor and muscle and on hind limb blood flow. GLUT1 expression quantification did not significantly differ between the study groups. Conclusion: The present study shows that succinate stimulates 18F-FDG uptake by endothelial cells, a finding that partially explains the 18F-FDG metabotype observed in tumors with SDH deficiency. Although this study is an 18F-FDG-based approach, it provides an impetus to better characterize the determinants of 18F-FDG uptake in various tumors and their surrounding microenvironment, with a special emphasis on the role of tumor-specific oncometabolites.
In recent years, inherited and acquired mutations in the tricarboxylic acid (TCA) cycle enzymes have been reported in diverse cancers. Pheochromocytomas and paragangliomas often exhibit dysregulation of glucose metabolism, which is also driven by mutations in genes encoding the TCA cycle enzymes or by activation of hypoxia signaling. Pheochromocytomas and paragangliomas associated with succinatedehydrogenase (SDH) deficiency are characterized by high 18F-FDG avidity. This association is currently only partially explained. Therefore, we hypothesized that accumulation of succinate due to the TCA cycle defect could be the major connecting hub between SDH-mutated tumors and the 18F-FDG uptake profile. Methods: To test whether succinate modifies the 18F-FDG metabolic profile of tumors, we performed in vitro and in vivo (small-animal PET/CT imaging and autoradiography) experiments in the presence of succinate, fumarate, and phosphate-buffered saline (PBS) in different cell models. As a control, we also evaluated the impact of succinate on 18F-fluorocholine uptake and retention. Glucose transporter 1 (GLUT1) immunohistochemistry was performed to assess whether 18F-FDG uptake correlates with GLUT1 staining. Results: Intratumoral injection of succinate significantly increased 18F-FDG uptake at 24 h on small-animal PET/CT imaging and autoradiography. No effect of succinate was observed on cancer cells in vitro, but interestingly, we found that succinate caused increased 18F-FDG uptake by human umbilical vein endothelial cells in a concentration-dependent manner. No significant effect was observed after intratumoral injection of fumarate or PBS. Succinate, fumarate, and PBS have no effect on cell viability, regardless of cell lineage. Intramuscular injection of succinate also significantly increases 18F-FDG uptake by muscle when compared with either PBS or fumarate, highlighting the effect of succinate on connective tissues. No difference was observed between PBS and succinate on 18F-fluorocholine uptake in the tumor and muscle and on hind limb blood flow. GLUT1 expression quantification did not significantly differ between the study groups. Conclusion: The present study shows that succinate stimulates 18F-FDG uptake by endothelial cells, a finding that partially explains the 18F-FDG metabotype observed in tumors with SDH deficiency. Although this study is an 18F-FDG-based approach, it provides an impetus to better characterize the determinants of 18F-FDG uptake in various tumors and their surrounding microenvironment, with a special emphasis on the role of tumor-specific oncometabolites.
Authors: J U Rao; U F H Engelke; F C G J Sweep; K Pacak; B Kusters; A G Goudswaard; A R M M Hermus; A R Mensenkamp; G Eisenhofer; N Qin; S Richter; H P M Kunst; H J L M Timmers; R A Wevers Journal: J Clin Endocrinol Metab Date: 2014-12-02 Impact factor: 5.958
Authors: Arthur Varoquaux; Yann le Fur; Alessio Imperiale; Antony Reyre; Marion Montava; Nicolas Fakhry; Izzie-Jacques Namer; Guy Moulin; Karel Pacak; Maxime Guye; David Taïeb Journal: Endocr Relat Cancer Date: 2015-06-26 Impact factor: 5.678
Authors: P J Pollard; J J Brière; N A Alam; J Barwell; E Barclay; N C Wortham; T Hunt; M Mitchell; S Olpin; S J Moat; I P Hargreaves; S J Heales; Y L Chung; J R Griffiths; A Dalgleish; J A McGrath; M J Gleeson; S V Hodgson; R Poulsom; P Rustin; I P M Tomlinson Journal: Hum Mol Genet Date: 2005-06-29 Impact factor: 6.150
Authors: Przemyslaw Sapieha; Mirna Sirinyan; David Hamel; Karine Zaniolo; Jean-Sébastien Joyal; Jang-Hyeon Cho; Jean-Claude Honoré; Elsa Kermorvant-Duchemin; Daya R Varma; Sophie Tremblay; Martin Leduc; Lenka Rihakova; Pierre Hardy; William H Klein; Xiuqian Mu; Orval Mamer; Pierre Lachapelle; Adriana Di Polo; Christian Beauséjour; Gregor Andelfinger; Grant Mitchell; Florian Sennlaub; Sylvain Chemtob Journal: Nat Med Date: 2008-10-05 Impact factor: 53.440
Authors: Charlotte Lussey-Lepoutre; Kate E R Hollinshead; Christian Ludwig; Mélanie Menara; Aurélie Morin; Luis-Jaime Castro-Vega; Seth J Parker; Maxime Janin; Cosimo Martinelli; Chris Ottolenghi; Christian Metallo; Anne-Paule Gimenez-Roqueplo; Judith Favier; Daniel A Tennant Journal: Nat Commun Date: 2015-11-02 Impact factor: 17.694
Authors: Hiren V Patel; Arnav Srivastava; Murray D Becker; Toni Beninato; Amanda M Laird; Eric A Singer Journal: Curr Urol Rep Date: 2021-01-06 Impact factor: 3.092
Authors: Anouk van Berkel; Dennis Vriens; Eric P Visser; Marcel J R Janssen; Martin Gotthardt; Ad R M M Hermus; Lioe-Fee de Geus-Oei; Henri J L M Timmers Journal: J Nucl Med Date: 2018-11-09 Impact factor: 10.057
Authors: David Taïeb; Rodney J Hicks; Elif Hindié; Benjamin A Guillet; Anca Avram; Pietro Ghedini; Henri J Timmers; Aaron T Scott; Saeed Elojeimy; Domenico Rubello; Irène J Virgolini; Stefano Fanti; Sona Balogova; Neeta Pandit-Taskar; Karel Pacak Journal: Eur J Nucl Med Mol Imaging Date: 2019-06-29 Impact factor: 9.236
Authors: Ruth T Casey; Mary A McLean; Basetti Madhu; Benjamin G Challis; Rogier Ten Hoopen; Thomas Roberts; Graeme R Clark; Deborah Pittfield; Helen L Simpson; Venkata R Bulusu; Kieran Allinson; Lisa Happerfield; Soo-Mi Park; Alison Marker; Olivier Giger; Eamonn R Maher; Ferdia A Gallagher Journal: JCO Precis Oncol Date: 2018-03-29